Clinical trials: Cyclophosphamide Reduced-dose
Acute Lymphoblastic Leukemia
A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)
The current national acute lymphoblastic leukaemia (ALL) trial in adults investigated whether a low (reduced) intensity chemotherapy regimen prior to transplant could improve the outcome of patients with ALL who are over 40 years…
- Trial name
- ALL-RIC (NCT03821610)
- Testing
- Fludarabine, Melphalan, Alemtuzumab
- Where
- 22 sites in United Kingdom
- Volunteers
- 242 people
- Sponsor
- University of Birmingham
Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Background: Blood cancers (such as leukemias or lymphomas) often do not respond to standard treatments. A transplant of blood stem cells from a healthy donor can help people with these cancers.
- Trial name
- NCT05436418
- Testing
- Melphalan, Sirolimus, Total Body Irradiation (TBI)
- Where
- 2 sites in United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Myelodysplastic Syndrome, Acute Leukemia
Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is regarded as a curative therapy for a variety of hematological malignancies and nonmalignant diseases.
- Trial name
- NCT06984536
- Testing
- Reduced ATG plus mini PTCy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Haploidentical Hematopoietic Stem Cell Transplant, Hematological Malignancies
To Study Lower Dose of Cyclophosphamide After Stem Cell Transplant for Blood Cancers
Cyclophosphamide is the name of a medicine given to prevent graft-versus-host-disease (GVHD) after half-matched transplant. This medicine is given on the 3rd and 4th day after stem cell transplant.
- Trial name
- NCT07719946
- Testing
- Cyclophosphamide
- Where
- 2 sites in India
- Volunteers
- 20 people
- Sponsor
- Tata Memorial Centre
Graft Versus Host Disease
Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC
Acute or chronic graft versus host disease is still the major complication of stem cells transplantation regarding morbidity and mortality.
- Trial name
- CYRIC (NCT03263767)
- Testing
- Fludarabine, Clofarabine, Full body irradiation
- Where
- France
- Volunteers
- 47 people
- Sponsor
- Nantes University Hospital
Hematological Malignancy
Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis
The purpose of this study is to determine if Bortezomib, known commercially as Velcade is safe and tolerated at different dose levels (amounts) with high dose Cyclophosphamide to be used as graft versus host disease prevention…
- Trial name
- NCT01860170
- Testing
- Cohort 1-Bortezomib (Velcade ®), Cohort 2-Bortezomib (Velcade ®), Cohort 3-Bortezomib (Velcade ®)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Corewell Health West
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
This phase II trial tests how well dose-reduced docetaxel combined with cyclophosphamide works in treating older women with early stage (stage I-III) HER2 negative breast cancer vulnerable to toxicity.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma
- Trial name
- NCT06042569
- Testing
- Cyclophosphamide, Docetaxel, Medical Chart Review
- Where
- 3 sites in United States
- Volunteers
- 174 people
- Sponsor
- City of Hope Medical Center
Allogeneic Hematopoietic Cell Transplant, Graft Versus Host Disease
Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation
This is a multi-center randomized study to compare the reduced-dose of post-transplantation cyclophosphamide (PTCY) at 35mg.kg to standard dose at 50mg/kg combined with tacrolimus and post-engraftment low dose anti-thymoglobin…
- Trial name
- NCT06705062
- Testing
- reduced-dose PTCy, Standard dose PTCY
- Where
- China
- Volunteers
- 316 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Lymphoma, Leukemia
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
This research is being done to learn more about reduced-intensity bone marrow transplantation (BMT), also known as a "mini" transplant for patients with blood cancers, using bone marrow from a relative.
- Conditions
- Lymphoma, Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01135329
- Testing
- Fludarabine, Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Graft Vs Host Disease
Post-transplantation Cyclophosphamide in Haploidentical Stem Cell Allografts Dose Reduction: 50 mg/kg vs 25 mg/kg
Allogeneic hematopoietic cell transplantation (HSCT) is a worldwide recognized therapy for several hematologic malignancies; a modality extensively used around the world due to its effectivity; however, an HLA-matched sibling or…
- Trial name
- NCT05780554
- Testing
- Cyclophosphamide
- Where
- Mexico
- Volunteers
- 42 people
- Sponsor
- Centro de Hematología y Medicina Interna
Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
This pilot phase II trial studies how well high dose cyclophosphamide, tacrolimus, and mycophenolate mofetil work in preventing graft versus host disease in patients with hematological malignancies undergoing myeloablative or…
- Conditions
- Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03128359
- Testing
- Busulfan, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- City of Hope Medical Center
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) .
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes
- Trial name
- OPTIMIZE (NCT06001385)
- Testing
- Busulfan, Fludarabine, PBSC Hematopoietic Stem Cell Transplantation (HSCT)
- Where
- 32 sites in United States
- Volunteers
- 313 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Graft Vs Host Disease
Cyclophosphamide, Abatacept, and Tacrolimus for the Prevention of GvHD
This is a single arm, open label, phase II clinical trial. Adult patients with hematological malignancies undergoing allogeneic HSCT from first- or second-degree haploidentical donor are eligible for the study if they meet the…
- Trial name
- NCT05621759
- Testing
- Cyclophosphamide, Abatacept, Tacrolimus
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- NYU Langone Health
Severe Aplastic Anemia, Cyclophosphamide Reduced-dose
Reduced Dose of Cyclophosphamide Combined With Standard Immunosuppressive Therapy to Treat Severe Aplastic Anemia
This is a prospective, single-center, single-arm, phase 2 study. This study aims to evaluate the efficacy and safety of anti-lymphocyte globulin plus herombopag in combination with the reduced dose of cyclophosphamide (hypo-CASH)…
- Conditions
- Severe Aplastic Anemia, Cyclophosphamide Reduced-dose, Immunosuppressive Therapy
- Trial name
- hypo-CASH (NCT06695741)
- Testing
- Reduced dose of cyclophosphamide combined with standard immunosuppressive therapy
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
This phase II trial tests how well lifileucel, with reduce dose fludarabine and cyclophosphamide for lymphodepletion and interleukin-2, work for treating patients with melanoma that cannot be removed by surgery (unresectable) or…
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Unresectable Melanoma
- Trial name
- NCT06151847
- Testing
- Biospecimen Collection, Cyclophosphamide, Echocardiography
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Kansas Medical Center
GVHD
Comparison of Different Dose of Post-transplantation Cyclophosphamide as Graft Versus Host Disease Prophylaxis
Post-transplantation cyclophosphamide (PTCY) is considered as major graft versus host disease (GVHD) prophylaxis. In our previous study, the investigators demonstrated that the standard dose PTCY of 50mg/kg with tacrolimus and…
- Trial name
- NCT06000982
- Testing
- PTCY
- Where
- 2 sites in China
- Volunteers
- 138 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
GVHD - Graft-Versus-Host Disease, HSCT
Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Phase III comparative, open-label, randomized (1:1) trial designed to evaluate the efficacy of reducing the total dose of PTCy to 70 mg/kg on GREFS compared to the standard dose of 100 mg/kg, in patients undergoing haploidentical…
- Conditions
- GVHD - Graft-Versus-Host Disease, HSCT, Haploidentical Stem Cell Transplantation
- Trial name
- REDUCy (NCT07193420)
- Testing
- Cyclophosphamide 35mg/kg/day, Cyclophosphamide 50mg/kg/day
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Myeloma in Relapse
Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMM
This is an open-label clinical study to evaluate the efficacy and safety of a multicenter, open-label clinical study of a base-reduced-dose pomalidomide, cyclophosphamide combined with dexamethasone (PCd) regimen for the…
- Trial name
- NCT06255847
- Testing
- Pomalidomide, cyclophosphamide combined with dexametha
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Shanxi Bethune Hospital